Cargando…

Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Background: Serum tumor markers carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cytokeratin 19 fragment (CYFRA21-1) and squamous-cell carcinoma-related antigen (SCC-Ag) are routinely used for monitoring the response to chemotherapy or targeted therapy in advanced-stage non-small cell lun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhibo, Yuan, Fang, Chen, Runzhe, Li, Ye, Ma, Junxun, Yan, Xiang, Wang, Lijie, Zhang, Fan, Tao, Haitao, Guo, Dong, Huang, Zhiyue, Zhang, Sujie, Li, Xiaoyan, Zhi, Xiaoyu, Ge, Xiangwei, Hu, Yi, Wang, Jinliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298878/ https://www.ncbi.nlm.nih.gov/pubmed/32587591 http://dx.doi.org/10.3389/fimmu.2020.01173

Ejemplares similares

Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Zhang, Zhibo, et al.
Publicado: (2020)

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
por: Ge, Xiangwei, et al.
Publicado: (2020)

Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
por: Sun, Danyang, et al.
Publicado: (2018)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials
por: Zhai, Jinzhao, et al.
Publicado: (2022)

Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors
por: Chen, Shixue, et al.
Publicado: (2021)

Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors
por: Chen, Shixue, et al.
Publicado: (2020)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
por: Chen, Shixue, et al.
Publicado: (2021)

Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade
por: Shang, Jin, et al.
Publicado: (2021)

Decreased expression of RASSF10 correlates with poor prognosis in patients with colorectal cancer
por: Ma, Junxun, et al.
Publicado: (2017)

Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis
por: Cui, Pengfei, et al.
Publicado: (2023)

Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study
por: Li, Xiaoyan, et al.
Publicado: (2022)

Swainsonine Inhibits Invasion and the EMT Process in Esophageal Carcinoma Cells by Targeting Twist1
por: Ma, Junxun, et al.
Publicado: (2018)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
por: Zhang, Fan, et al.
Publicado: (2020)

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Can Mean Platelet Volume Serve as a Marker for Prostatitis?
por: Karaman, Hatice, et al.
Publicado: (2013)

Efficacy of Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural or Peritoneal Effusions
por: ZHANG, Xin, et al.
Publicado: (2013)

Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
por: Zhang, Zhibo, et al.
Publicado: (2019)

CXCL2 Impairs Functions of Bone Marrow Mesenchymal Stem Cells and Can Serve as a Serum Marker in High-Fat Diet-Fed Rats
por: Bi, Jianhai, et al.
Publicado: (2021)

Can presence of oral Fordyce's granules serve as a marker for hyperlipidemia?
por: Gaballah, Kamis Y., et al.
Publicado: (2014)

High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic Marker
por: Papadakos, Konstantinos S., et al.
Publicado: (2019)

Two Novel Long Noncoding RNAs – RP11-296E3.2 and LEF1-AS1can – Separately Serve as Diagnostic and Prognostic Bio-Markers of Metastasis in Colorectal Cancer
por: Shi, Qian, et al.
Publicado: (2019)

MicroRNA-98 can serve as a diagnostic marker for congenital heart disease-associated pulmonary artery hypertension
por: Zhang, Yao-Zhong, et al.
Publicado: (2020)

Circulating microRNAs Serve as Novel Biological Markers for Intracranial Aneurysms
por: Li, Pengxiang, et al.
Publicado: (2014)

Serum miR-128-2 Serves as a Prognostic Marker for Patients with Hepatocellular Carcinoma
por: Zhuang, Liping, et al.
Publicado: (2015)

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
por: Wang, Chunyu, et al.
Publicado: (2023)

Serum exosomal miR‐1269a serves as a diagnostic marker and plays an oncogenic role in non‐small cell lung cancer
por: Wang, Xue, et al.
Publicado: (2020)

Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer's Disease
por: Dong, Hui, et al.
Publicado: (2015)

Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study
por: Liu, Qingyan, et al.
Publicado: (2023)

CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer
por: Tang, Shasha, et al.
Publicado: (2022)

SMYD Family Members Serve as Potential Prognostic Markers and Correlate with Immune Infiltrates in Gastric Cancer
por: Liu, Donghui, et al.
Publicado: (2023)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease?
por: Das, Undurti N
Publicado: (2008)

Dysregulated Expression of Circular RNAs Serve as Prognostic and Clinicopathological Markers in Cancer
por: Huang, Xin, et al.
Publicado: (2019)

Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2017)

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023)

Conditional transcriptional relationships may serve as cancer prognostic markers
por: Yu, Hui, et al.
Publicado: (2021)

Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer
por: Liu, Jing-bo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mj329388hmdc5t65llp7u0483c